PalinGen Flow for Chronic Lower Extremity Ulcers

Phase 2, randomised, open-label trial in diabetic foot ulcer (DFU) and venous leg ulcer (VLU) (2 arms), sponsored by Amnio Technology. Primary endpoints: Proportion of participants with treatment-emergent adverse events at 64 weeks and Proportion of participants who achieve complete ulcer closure at 12 weeks. Started Jan 2021; status: active, not recruiting.